Medtronic has received the CE mark for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronisation therapy-defibrillators (CRT-D). With the launch of the Cobalt and Crome platform, Medtronic also is making TriageHF technology available. A press release reports that this technology assesses patients’ heart failure risk through a simplified, integrated, automatic tool that identifies patient status changes that may lead to worsening heart failure and hospitalisation.
The press release adds that TriageHF stratifies patients into three risk categories (high, medium or low) by evaluating factors such as heart rate variability, atrial fibrillation and fluid status. The TriageHF assessment tool is designed to be compatible with all Medtronic ICDs and CRT-Ds with the Medtronic OptiVol fluid status monitoring feature, including those currently implanted in patients.
According to the press release, this newest generation of implantable heart devices also includes several “smart” features:
- Intrinsic ATP (iATP), available on Cobalt XT ICDs and CRT-Ds, is the only automated algorithm that adapts to a patient’s irregular heart rhythms and attempts to reset them with painless pacing therapy, possibly avoiding the need for shocks. This ventricular anti-tachycardia pacing (ATP) provides individualised therapy in real-time and is paired with Medtronic-exclusive SmartShock 2.0 shock-reduction technology. The devices also feature improved longevity and energy output.
- This is the first Medtronic ICD and CRT-D portfolio to offer connected health with BlueSync technology, which enables the implanted devices to communicate with the tablet-based CareLink SmartSync device manager for physicians, and the MyCareLink Heart mobile app for patients.
- The new CRT-Ds also include the EffectivCRT algorithm and the AdaptivCRT algorithm, which is designed to adjust therapy according to minute-by-minute evaluations of each patient’s heart rhythm. AdaptivCRT has been shown to increase patients’ response to CRT; reduce unnecessary right ventricular pacing; reduce the likelihood of 30-day heart failure hospital readmissions; and reduce the risk of atrial fibrillation. Additionally, AdaptivCRT is associated with improved patient survival.
Klaus Witte (School of Medicine, University of Leeds, Leeds, UK) says: “Cobalt and Crome heart devices deliver the opportunity of a personalized approach to defibrillator therapy, demonstrating how far we have come in this field. Moreover, these devices offer seamless patient care through their ability to transmit device and patient data via smartphone or tablet.”
Rob Kowal (chief medical officer of the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic) notes: “The Cobalt and Crome devices demonstrate our commitment to enhancing device connectivity and personalised patient care. These advancements will help physicians respond to patients’ individual needs through informed clinical decision making, potentially improving the outcomes of patients around the world.”